Meeting
2018 Gastrointestinal Cancers Symposium
Phase 1 studies of 3- and 6-peptide vaccine cocktail derived from GPC3, WDRPUH, and NEIL3 in patients with advanced hepatocellular carcinoma (HCC).
Authors
Masafumi Ikeda
National Cancer Center Hospital East, Kashiwa, Japan
Masafumi Ikeda , Takuji Okusaka , Izumi Ohno , Shuichi Mitsunaga , Hideaki Takahashi , Shunsuke Kondo , Chigusa Morizane , Junji Furuse
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
JapicCTI-121933 and JapicCTI-142477
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 387)
DOI
10.1200/JCO.2018.36.4_suppl.387
Abstract #
387
Poster Bd #
J1
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Phase I study of a new concept cancer vaccine composed artificial intelligence (AI)-designed shared-antigen peptides plus combined synergistically activating antigen-specific CTL reaction (CYT001) in patients with advanced hepatocellular carcinoma (CRESCENT 1).
First Author: Sadahisa Ogasawara
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
First-in-human study of the cancer peptide vaccine, TAS0313, in patients with advanced solid tumors: Phase I dose-finding part results.
First Author: Noboru Yamamoto
Poster
2023 ASCO Annual Meeting
Phase 1 trial evaluating TTI-101, a first-in-class, orally bioavailable, small molecule, inhibitor of STAT3, in patients with advanced solid tumors.
First Author: Apostolia Maria Tsimberidou
First Author: Snehal Patel